Mind Medicine Inc’s recent filing unveils that its Chief Executive Officer Barrow Robert unloaded Company’s shares for reported $0.16 million on Mar 25 ’24. In the deal valued at $9.50 per share,16,519 shares were sold. As a result of this transaction, Barrow Robert now holds 580,202 shares worth roughly $5.24 million.
Then, Karlin Dan sold 6,578 shares, generating $62,491 in total proceeds. Upon selling the shares at $9.50, the Chief Medical Officer now owns 358,452 shares.
Before that, Barrow Robert sold 13,237 shares. Mind Medicine Inc shares valued at $48,050 were divested by the Chief Executive Officer at a price of $3.63 per share. As a result of the transaction, Barrow Robert now holds 596,721 shares, worth roughly $5.39 million.
Leerink Partners initiated its Mind Medicine Inc [MNMD] rating to an Outperform in a research note published on April 15, 2024; the price target was $20. A number of analysts have revised their coverage, including Canaccord Genuity’s analysts, who began to cover the stock in early December with a ‘”a Buy”‘ rating. RBC Capital Mkts started covering the stock on November 16, 2022. It rated MNMD as “an Outperform”.
Price Performance Review of MNMD
On Monday, Mind Medicine Inc [NASDAQ:MNMD] saw its stock jump 5.99% to $9.03. Over the last five days, the stock has gained 4.03%. Mind Medicine Inc shares have risen nearly 146.72% since the year began. Nevertheless, the stocks have risen 142.74% over the past one year. While a 52-week high of $12.22 was reached on 04/04/24, a 52-week low of $2.41 was recorded on 01/19/24. SMA at 50 days reached $8.46, while 200 days put it at $4.84. A total of 1.24 million shares were traded, compared to the trading of 0.83 million shares in the previous session.
Levels Of Support And Resistance For MNMD Stock
The 24-hour chart illustrates a support level at 8.53, which if violated will result in even more drops to 8.02. On the upside, there is a resistance level at 9.36. A further resistance level may holdings at 9.68. The Relative Strength Index (RSI) on the 14-day chart is 49.36, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.57, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 69.54%. Stochastics %K at 17.93% indicates the stock is a buying.
The most recent change occurred on August 26, 2022 when Oppenheimer began covering the stock and recommended ‘”an Outperform”‘ rating along with a $3.50 price target.
